MSN Laboratories is an API and finished-dose manufacturer based in India. It holds 517 active US drug master files and 121 valid CEPs. Its filings concentrate with ARCSA (EC), MHRA (UK) and CDSCO (India). Its GMP standing is certified by EDQM, EMA and ANVISA (Brazil), among 12 authorities. Its most recent recorded inspection, by US FDA, closed on 13 March 2026 as NAI. Customs aggregates show $231.3M of exports covering 3,882 molecules to 89 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Rangareddy, United Arab Emirates | Not on file |
| Telangana, Colombia | Not on file |
| HITCHIN, United Kingdom | Not on file |
| LETCHWORTH GARDEN CITY, United Kingdom | Not on file |
| Kardanur Village, India | Not on file |
| Kandi Mandal, India | Not on file |
30 further sites are on record.
| Molecule | Regulators | Docs |
|---|---|---|
| Dapagliflozin | SFDA (Saudi Arabia), US FDA | 10 |
| Esomeprazole | EDQM, SFDA (Saudi Arabia), US FDA | 10 |
| Sitagliptin | EDQM, SFDA (Saudi Arabia), US FDA | 9 |
| Rosuvastatin | EDQM, SFDA (Saudi Arabia), US FDA | 7 |
| Clopidogrel | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Mebendazole | EDQM, US FDA | 6 |
| Metoprolol | EDQM, US FDA | 6 |
| Pantoprazole | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Posaconazole | SFDA (Saudi Arabia), US FDA | 6 |
| Pregabalin | EDQM, SFDA (Saudi Arabia), US FDA | 6 |
| Rivastigmine | EDQM, US FDA | 6 |
| Ruxolitinib | SFDA (Saudi Arabia), US FDA | 6 |
| Sacubitril | SFDA (Saudi Arabia), US FDA | 6 |
| Atorvastatin | SFDA (Saudi Arabia), US FDA | 5 |
| Bosutinib | SFDA (Saudi Arabia), US FDA | 5 |
| Carboprost | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Carfilzomib | SFDA (Saudi Arabia), US FDA | 5 |
| Eplerenone | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Ezetimibe | PMDA (Japan), SFDA (Saudi Arabia), US FDA | 5 |
| Gefitinib | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Moxifloxacin | SFDA (Saudi Arabia), US FDA | 5 |
| Nilotinib | SFDA (Saudi Arabia), US FDA | 5 |
| Pirfenidone | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Riociguat | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Tadalafil | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Teriflunomide | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Ticagrelor | EDQM, SFDA (Saudi Arabia), US FDA | 5 |
| Tofacitinib | SFDA (Saudi Arabia), US FDA | 5 |
| Vigabatrin | EDQM, US FDA | 5 |
| Abiraterone | SFDA (Saudi Arabia), US FDA | 4 |
| Apremilast | US FDA | 4 |
| Cabozantinib | US FDA | 4 |
| Capecitabine | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Clobazam | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Clopidogrel Hydrogen Sulfate | EDQM | 4 |
| Dasatinib | SFDA (Saudi Arabia), US FDA | 4 |
| Deferasirox | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Docetaxel | EDQM, US FDA | 4 |
| Duloxetine | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
| Dutasteride | EDQM, SFDA (Saudi Arabia), US FDA | 4 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| ARCSA (EC) | 147 | None |
| MHRA (UK) | 140 | 5 |
| CDSCO (India) | 125 | 2 |
| DIGEMAPS (DO) | 104 | None |
| US FDA | 103 | 6 |
| TMDA (TZ) | 94 | None |
| EDQM | None | 30 |
| EMA | None | 13 |
| ANVISA (Brazil) | None | 10 |
| MFDS (Korea) | None | 6 |
| UZPHARM (UZ) | None | 2 |
| FDA (GH) | None | 1 |
| NAFDAC (NG) | None | 1 |
| EAEU_EEC | None | 1 |
| INVIMA (CO) | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $106.8M | 93 |
| 2025 | Not reported | $231.3M | 89 |
| 2024 | Not reported | $207.9M | 82 |
| 2023 | Not reported | $214.7M | 78 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.
Choose your molecules and target markets. MSN Laboratories comes back tiered against every other supplier able to file there.
Start for freeRanked by shared active ingredients where we have them, otherwise by country and comparable credentials.